{"id":"W4206062027","doi":"10.1016/j.ejca.2021.12.012","title":"Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Hamilton Health Sciences; Kingston Health Sciences Centre; Queen's University","funders":"Genentech; Servier; Cilag; Astellas Pharma; Incyte; Ipsen; Clovis Oncology; Strong; Sanofi; Exelixis; Eisai; Pfizer; Les Laboratories Pierre Fabre; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Clinical endpoint; Internal medicine; Adverse effect; Population; Urology; Tolerability; Phases of clinical research; Oncology; Surgery; Chemotherapy; Clinical trial; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004372532,0.001506998,0.001938892,0.0003150972,0.0005165708,0.00095594,0.0009845983,0.001045158,0.003829343],"category_scores_gemma":[0.001685508,0.0006034991,0.001496227,0.0003692336,0.000840267,0.0008658115,0.0004204245,0.002383689,0.001215892],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009387831,"about_ca_system_score_gemma":0.001753977,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006285129,"about_ca_topic_score_gemma":0.00240884,"domain_scores_codex":[0.9989595,0.0005998376,0.0000742401,0.0001442579,0.0001167197,0.0001054911],"domain_scores_gemma":[0.9984065,0.0002538432,0.0004147362,0.0001419287,0.0001452818,0.0006376758],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7524784,0.07872833,0.03331085,0.001606054,0.004824576,0.0003781965,0.0003252462,0.002139466,0.0357376,0.0002444285,0.008380608,0.08184629],"study_design_scores_gemma":[0.6006277,0.3437444,0.04495548,0.00005688705,0.001408319,0.0004238012,0.00006203369,0.0009606789,0.003386377,0.0001559482,0.004177239,0.00004114482],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886793,0.003186307,0.000545004,0.0005177394,0.00008560876,0.002589282,0.002190642,0.00008680668,0.002119339],"genre_scores_gemma":[0.9878923,0.001519435,0.001615055,0.001174933,0.000153524,0.002313468,0.003522122,0.00003467992,0.001774457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004372532,"threshold_uncertainty_score":0.02312446,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04576036169986496,"score_gpt":0.3418975716791859,"score_spread":0.2961372099793209,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}